Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease

American Journal of Gastroenterology

Volumn 98, Issue 3 SUPPL., 2003, Pages

  Fass, Ronnie ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b S AZ Vet Aff Health Care System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; BODY WEIGHT; CLINICAL FEATURE; CONFERENCE PAPER; ESOPHAGUS MOTILITY; GASTROESOPHAGEAL REFLUX; HEARTBURN; HIATUS HERNIA; HUMAN; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; SEX DIFFERENCE;

EID: 0037343795     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(03)00009-1     Document Type: Conference Paper

References (51)

1. Locke GR III, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997;112:1448-56.
2. A Gallup Organization National Survey. Heartburn Across America. Princeton, NJ: Gallup Organization, 1988.
3. Smout AJ. Endoscopy-negative acid reflux disease. Aliment Pharmacol Ther 1997;11(suppl 2):81-5.
4. Richter JE. Long-term management of gastroesophageal reflux disease and its complications. Am J Gastroenterol 1997;92(suppl 4):S30-5.
5. Fass R. Focused clinical review: nonerosive reflux disease. Medscape Gastroenterol 2001;3:1-15.
6. Fass R, Ofman JJ, Gastroesophageal reflux disease - should we adopt a new conceptual framework? Am J Gastroenterol. 2002;97:1901-9.
7. Bate CM, Griffin SM, Keeling PW, et al. Reflux symptom relief with omeprazole in patients with unequivocal oesophagitis. Aliment Pharmacol Ther 1996;10:547-55.
8. Lind T, Havelund T, Carlsson R, et al. Heartburn withoutoesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997;32:974-9.
9. Venables TL, Newland RD, Patel AC, et al. Omeprazole 10 mg once daily, omeprazole 20 mg once daily, or ranitidine 150 mg twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997;32:965-73.
10. Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997;11:765-73.
11. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 1998;10:119-24.
12. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001;96:656-65.
13. Richter JE, Peura D, Benjamin SB, et al. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med 2000;160:1810-6.
14. Kahrilas PJ. Gastroesophageal reflux disease and its complications. In: Feldman M, Scharschmidt BF, Sleisenger MH, eds. Sleisenger and Fordtran's gastrointestinal and liver disease: pathophysiology, diagnosis, management, 6th ed. Philadelphia: WB Saunders, 1998:584.
15. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management: the Genval Workshop Report. Gut 1999;44(suppl 2):S1-16.
16. Waring JP. Nonerosive reflux disease. Semin Gastrointest Dis 2001;12:33-7.
17. Fass R, Naliboff B, Higa L, et al. Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans. Gastroenterology 1998;115:1363-73.
18. Mittal RK, Gui A, Liu J. The sustained esophageal contraction associated with heartburn of a positive Bernstein test is mediated through a non-cholinergic pathway (abstract). Gastroenterology 2001:120(5 suppl 1):A-421.
19. Sifrim D, Holloway R, Silny J, et al. Acid, nonacid, and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-hour pH-impedance recordings. Gastroenterology 2001;120:1588-98.
20. Vela MF, Camacho-Lobato L, Srinivasan R, et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001;120:1599-606.
21. Fass R, Tougas G. Functional heartburn - the stimulus, the pain and the brain. Gut. 2002;51:885-92.
22. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease current concepts and dilemmas. Am J Gastroenterol 2001;96:303-14.
23. Winters C Jr, Spurling TJ, Chobanian SJ, et al. Barrett's esophagus. A prevalent occult complication of gastroesophageal reflux disease. Gastroenterology 1987;92:118-24.
24. Johansson KE, Ask P, Boeryd B, et al. Oesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease. Scand J Gastroenterol 1986;21:837-47.
25. Jones RH, Hungin AP, Phillips J, et al. Gastro-esophageal reflux disease in primary care in Europe: clinical presentation and endoscopic findings. Eur J Gen Pract 1995;1:149-54.
26. Robinson M, Earnest D, Rodriguez-Stanley S, et al. Heartburn requiring frequent antacid use may indicate significant illness. Arch Intern Med 1998;158:2373-6.
27. Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999;13:907-14.
28. Pace F, Santulucia F, Bianchi Porro GB. Natural history of gastro-oesophageal reflux disease without oesophagitis. Gut 1991;32:845-8.
29. Isolauri J, Luostarinen M, Isolauri E, et al. Natural course of gastroesophageal reflux disease: 17-22-year follow-up of 60 patients. Am J Gastroenterol 1997;92:37-41.
30. Fenton P, Terry ML, Galloway KD, et al. Is there a role for laparoscopic fundoplication in patients with non-erosive reflux disease (NERD) (abstract)? Gastroenterology 2000;118(4 suppl 2):A481. Abstract 2600.
31. Kahrilas PJ, Dodds WJ, Hogan WJ, et al. Oesophageal peristaltic dysfunction in peptic esophagitis. Gastroenterology 1986;91:897-904.
32. Cameron AJ. Barrett's esophagus: prevalence and size of hiatal hernia. Am J Gastroenterol 1999;94:2054-9.
33. van Herwaarden MA, Samsom M, Smout AJ. Excess gastroesophageal reflux in patients with hiatus hernia is caused by mechanisms other than transient LES relaxations. Gastroenterology 2000;119:1439-46.
34. Martinez SD, Malagon I, Garewal H, et al. Nonerosive reflux disease (NERD) - is it really just a mild form of gastroesophageal reflux disease (GERD) (abstract)? Gastroenterology 2001;120(suppl 1):A424.
35. Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996;111:1192-9.
36. Ferreira KT, Hill BS. The effect of low external pH on properties of the paracellular pathway and junctional structure in isolated frog skin. J Physiol 1982;332:59-67.
37. Hopwood D, Milne G, Logan KR. Electron microscopic changes in human oesophageal epithelium in oesophagitis. J Pathol 1979;129:161-7.
38. Tobey NA, Carson JL, Alkiek RA, et al. Dilated intercellular spaces: a morphological feature of acid reflux-damaged human esophageal epithelium. Gastroenterology 1996;111:1200-5.
39. Orlando RC. Pathophysiology of gastroesophageal reflux disease. In: Castell DO, Richter JE, eds. The esophagus, 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 1999:409-19.
40. Baldi F, Ferrarini F, Longanesi A, et al. Acid gastroesophageal reflux and symptom occurrence. Analysis of some factors influencing their association. Dig Dis Sci 1989;34:1890-3.
41. DeMeester TR, Wang CI, Wernly JA, et al. Technique, indications, and clinical use of 24 hour esophageal pH monitoring. J Thorac Cardiovasc Surg 1980;79:656-70.
42. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997;92:1997-2000.
43. Richter JE, Campbell DR, Kahrilas PJ, et al. Lansoprazole compared to ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med 2000;160:1803-6.
44. Clouse RE, Richter JE, Heading RC, et al. Functional esophageal disorders. In: Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE, eds. Rome II: the functional gastrointestinal disorders: diagnosis, pathophysiology, and treatment. McLean, VA: Degnon Associates. 2000:275.
45. Watson RG, Tham TC, Johnston BT, et al. Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux: the "sensitive oesophagus." Gut 1997;40:587-90.
46. Pehlivanov N, Liu J, Mittal RK. Sustained esophageal contraction: a motor correlate of heartburn symptom. Am J Physiol Gastrointest Liver Physiol 2001;281:G743-51.
47. Meyer JH, Lembo A, Elashoff JD, et al. Duodenal fat intensifies the perception of heartburn. Gut 2001;49:624-8.
48. Feinle C, Grundy D, Read NW. Effects of duodenal nutrients on sensory and motor responses of the human stomach to distension. Am J Physiol 1997;273:G721-6.
49. Barbera R, Feinle C, Read NW. Nutrient-specific modulation of gastric mechanosensitivity in patients with functional dyspepsia. Dig Dis Sci 1995;40:1636-41.
50. Trimble KC, Pryde A, Heading RC. Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut 1995;37:7-12.
51. Fass R, Malagon I, Naliboff BD, et al. Effect of psychologically induced stress on symptom perception and autonomic nervous system response of patients (PTS) with erosive esoph agitis (EE) and nonerosive reflux disease (NERD) (abstract). Gastroenterology 2000;118:A637. Abstract 3250.